Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cell and gene therapy manufacturing

- PMLiVE

GSK’s triple COPD therapy tops Symbicort in phase III trial

Once-daily, single inhaler combination treatment showed “significant” improvement in lung function

- PMLiVE

Ariad files early marketing application for brigatinib

Second-line lung cancer therapy could be on the market by early 2017

Deal Watch May 2016

Novartis, Quintiles and Sanofi are among those featured in this month’s round-up of pharma deal activity

- PMLiVE

GSK brings forward triple COPD therapy filing in US

Intends to file the three-drug respiratory therapy by the end of 2016

Biogen Idec building

Biogen and AbbVie bag FDA approval for multiple sclerosis drug

Once-monthly, self-administered Zinbryta ‘significantly’ reduces relapse rate

Novartis building

Novartis says Cosentyx is ‘outpacing competitors’

Claims new psoriasis drug has almost a third of the market share in Germany alone

Novartis Gehry Building

Novartis pushes the accelerator with new Entresto trials

Looks to kick-start sales of its heart failure drug with new study programme

- PMLiVE

Novartis funds chronic urticaria app and patient community

My Hives has been developed, and will be run, by Exco InTouch

Novartis day

Trial sets up showdown between Ibrance and Novartis’ ribociclib

Positive interim data could put the Swiss firm's breast cancer therapy in-line for early approval

Novartis building

Novartis splits pharma unit as Epstein exits

Restructure sees creation of standalone cancer arm Novartis Oncology

EISAI

Eisai gets green light for Lenvima in kidney cancer

New drug awarded breakthrough and priority review status by FDA in RCC

Eli Lilly HQ

Lilly’s psoriasis drug Taltz cleared in Europe

Clinicians suggest the IL-17 inhibitor has “best-in-class data”

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links